FREE ROUNDUP LAWSUIT EVALUATION — No Fees Unless You Win 1-800-555-0000
HomeMass Tort ClaimsRoundup LawsuitCancer Types That Qualify

Roundup Cancer Types
That Qualify for
a Lawsuit

Reviewed by: ClaimCheckUSA Medical Review TeamLast updated: March 26, 2026

Not every cancer diagnosis qualifies for a Roundup lawsuit. The litigation focuses on cancers where there is scientific evidence linking glyphosate exposure to increased risk — primarily Non-Hodgkin's Lymphoma (NHL) and its subtypes. Below is a complete breakdown of qualifying cancers and the strength of evidence supporting each.

Primary Qualifying Cancers

Non-Hodgkin's Lymphoma (NHL)

Strongest evidence

NHL is the primary qualifying cancer for Roundup lawsuits. It is a cancer of the lymphatic system. Multiple peer-reviewed studies, including a 2019 meta-analysis published in Mutation Research, found a 41% increased risk of NHL in people exposed to glyphosate.

Qualifying Subtypes:
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaMantle Cell LymphomaBurkitt Lymphoma

B-Cell Lymphoma

Strong evidence

B-cell lymphomas are a subgroup of NHL and represent the most common type seen in Roundup litigation. Bayer's own internal documents referenced in litigation showed awareness of B-cell lymphoma risks.

Qualifying Subtypes:
Diffuse Large B-Cell LymphomaFollicular LymphomaChronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma

T-Cell Lymphoma

Moderate evidence

T-cell lymphomas are less common than B-cell types but have also been linked to pesticide exposure in epidemiological studies.

Qualifying Subtypes:
Peripheral T-Cell LymphomaAnaplastic Large Cell LymphomaCutaneous T-Cell Lymphoma

Other Cancers — Evaluated Case-by-Case

Chronic Lymphocytic Leukaemia (CLL)
Some studies show association; may qualify depending on exposure history
Hairy Cell Leukaemia
Rare blood cancer; linked to pesticide exposure in several studies
Multiple Myeloma
Some epidemiological evidence; evaluated case-by-case
Myelodysplastic Syndrome
Pre-leukaemia condition; may qualify with strong exposure history

Were You Diagnosed with NHL After Using Roundup?

Free case evaluation. No fees unless you win. Takes 60 seconds.

Check My Roundup Eligibility

Frequently Asked Questions

What is the most common cancer in Roundup lawsuits?
Non-Hodgkin's Lymphoma (NHL) is by far the most common qualifying cancer. The majority of the 100,000+ Roundup claims that settled involved NHL diagnoses. Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma are the most frequently cited subtypes.
Does any cancer qualify for a Roundup lawsuit?
No. The lawsuits focus specifically on cancers with scientific evidence linking them to glyphosate exposure — primarily Non-Hodgkin's Lymphoma and its subtypes. Other cancers may qualify on a case-by-case basis, but NHL is the primary qualifying diagnosis.
How long after using Roundup can cancer develop?
Cancer can develop years or even decades after exposure. Most successful claims involve people who used Roundup regularly for several years before developing cancer. There is no specific minimum latency period, but longer and more intensive exposure generally strengthens the case.
Do I need a biopsy or pathology report to file a lawsuit?
Yes. You will need medical records confirming your cancer diagnosis, including pathology reports. Your attorney will help gather these records as part of the case evaluation process.